Acetazolamide Prophylaxis in Hypokalemic Periodic Paralysis

Publisher Website
Google Scholar
Abstract
When acetazolamide, an agent used to treat hyperkalemic periodic paralysis, was inadvertently found to relieve a patient with the hypokalemic variety, he and another patient were observed to compare this agent with conventional therapy. Well tolerated doses of acetazolamide, 375 to 500 mg daily, eliminated severe attacks and were much more effective than potassium or spironolactone. Preliminary results in five additional patients with hypokalemic periodic paralysis indicated that only three are improved. Two have not benefited.